People seem to be missing the most important part of this press release. Yes, these guys were easy pickings to make an example of because of the shady AAS stuff they had going on, but by including the part about 'other peptide products' (ie. glp's) the FDA kind of tipped their hand about how they intend to go after less shady companies slinging glp's on American soil starting next year. By already having set a precedent with Paradigm, it'll make it easier for them to apply it to other companies. They always go after the low hanging fruit first to set a precedent with a novel legal theory. This is the canary in the coal mine.
I've seen videos from several people in the community talking about how some of these companies got a tap on the shoulder from their lawyers having heard about what is about to come down the pike and that's why they're discontinuing selling glps. It's not to push promos. You couldn't pay me enough to sell a single vial of any peptide.
As far as getting stuff from China I read a post awhile ago from someone who had a friend in customs talking about how humans have been training AI to detect contraband during packages scans and while I'm sure they won't get them all, it could be devastating for the gray in the next few years. I believe the guy had said they wanted it up and running in full by mid to late 2026.
